Foresee Pharmaceuticals Co., Ltd. Stock price

Equities

6576

TW0006576002

Biotechnology & Medical Research

End-of-day quote Taipei Exchange 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
98 TWD +1.45% Intraday chart for Foresee Pharmaceuticals Co., Ltd. +3.27% +1.87%
Sales 2023 * 195M 6.09M Sales 2024 * 916M 28.61M Capitalization 13.31B 416M
Net income 2023 * -937M -29.26M Net income 2024 * -76M -2.37M EV / Sales 2023 * 68.5 x
Net Debt 2023 * 45M 1.41M Net Debt 2024 * 116M 3.62M EV / Sales 2024 * 14.7 x
P/E ratio 2023 *
-12.4 x
P/E ratio 2024 *
-153 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 66.81%
More Fundamentals * Assessed data
Dynamic Chart
Foresee Pharmaceuticals Co., Ltd. Announces Executive Changes, Effective March 31, 2024 CI
Foresee Pharmaceuticals Co., Ltd. Obtains the Official Pharmaceutical License of CAMCEVI 42 Mg from the Ministry of Health and Welfare in Taiwan CI
Foresee Pharmaceuticals Co., Ltd. Announces Last Patient Enrolled in the China Registration Clinical Trial of Leuprolide Injectable Emulsion in Prostate Cancer Has Completed Treatment CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Foresee Pharmaceuticals Co., Ltd. Submits Phase 3 IND (Investigational New Drug) Application to China NMPA CI
Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion, 42 mg for the Treatment of Central Precocious Puberty Patients CI
Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 Activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium CI
Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for Camcevi®, Extending Patent Protection to 2039 CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Member to the Compensation Committee CI
Foresee Pharmaceuticals to Present Allergic Asthma Study at European Medical Conference MT
Foresee Pharmaceuticals Co., Ltd. Appoints Ben Liu as Audit Committee Member CI
Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Independent Director CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Foresee Pharmaceuticals Co., Ltd. Announces Executive Changes CI
More news
1 day+1.45%
1 week+3.27%
Current month-7.11%
1 month-5.31%
3 months+1.66%
6 months+22.50%
Current year+1.87%
More quotes
1 week
94.50
Extreme 94.5
98.20
1 month
93.20
Extreme 93.2
106.00
Current year
92.50
Extreme 92.5
107.50
1 year
75.30
Extreme 75.3
128.50
3 years
69.50
Extreme 69.5
141.00
5 years
35.10
Extreme 35.1
141.00
10 years
35.10
Extreme 35.1
141.00
More quotes
Managers TitleAgeSince
Founder - 15-07-08
Chief Executive Officer - 13-02-07
Director of Finance/CFO 56 19-10-06
Members of the board TitleAgeSince
Director/Board Member 73 15-08-02
Chief Executive Officer - 13-02-07
Director/Board Member - 16-03-30
More insiders
Date Price Change Volume
24-03-27 98 +1.45% 193,412
24-03-26 96.6 -0.31% 134,735
24-03-25 96.9 +1.47% 161,776
24-03-22 95.5 +0.53% 148,773
24-03-21 95 +0.11% 108,364

End-of-day quote Taipei Exchange, March 26, 2024

More quotes
Foresee Pharmaceuticals Co., Ltd. is a Taiwan-based company mainly engaged in the research and development of new pharmaceuticals. The Company's main products include prostate cancer treatment product FP-001 and asthmatic/chronic obstructive pulmonary disease treatment product FP-025. It also engages in new pharmaceuticals clinic trial business.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
98 TWD
Average target price
153 TWD
Spread / Average Target
+56.12%
Consensus
  1. Stock
  2. Equities
  3. Stock Foresee Pharmaceuticals Co., Ltd. - Taipei Exchange